M. DAVID MACFARLANE, PH.D. - Corporate Board Profile

TITAN PHARMACEUTICALS INC

Filing Date	Source Excerpt
2002-07-15	M. David MacFarlane, Ph.D., has served on the Board of Directors since May 2002.
2003-07-14	Upon being elected director in May 2002, Dr. M. David MacFarlane received an option grant to purchase 10,000 shares of our common stock at an exercise price of $5.77.
2004-08-11	M. David MacFarlane, Ph.D., has served on the Board of Directors since May 2002.
2005-07-12	M. David MacFarlane, Ph.D., has served on the Board of Directors since May 2002.
2006-08-10	M. David MacFarlane, Ph.D. has served on the Board of Directors since May 2002. From 1989 until his retirement in August 1999, Dr. MacFarlane served as Vice President and Responsible Head of Regulatory Affairs of Genentech, Inc.
2007-08-15	M. David MacFarlane, Ph.D. has served on the Board of Directors since May 2002. The Audit Committee (which is formed in compliance with Section 3(a)(58)(A) of the Securities Exchange Act of 1934) consists of three directors, Ley S. Smith, M. David MacFarlane and Hubert E. Huckel. The Nominating Committee consists of three directors, Eurelio M. Cavalier, M. David MacFarlane and Ley S. Smith.
2008-04-03	M. David MacFarlane, Ph.D. has served on the Board of Directors since May 2002. From 1989 until his retirement in August 1999, Dr. MacFarlane served as Vice President and Responsible Head of Regulatory Affairs of Genentech, Inc. ... Member of Audit Committee ... Member of Nominating Committee ... Non-employee directors are entitled to receive a fee for each meeting attended ... During 2007, each director was granted an annual option to purchase 5,000 shares ... In addition to having their out-of-pocket expenses reimbursed, non-employee directors received $2,500 for each Board of Directors meeting attended in 2007. ... M. David MacFarlane, Ph.D. Fees Earned or Paid in Cash($): 15,000 ... Total: 28,878
2015-07-20	M. David MacFarlane, Ph.D. served as Vice President and Responsible Head of Regulatory Affairs of Genentech, Inc. from 1989 until his retirement in August 1999. Prior to joining Genentech, Inc., he served in various positions with Glaxo Inc., last as Vice President of Regulatory Affairs. Based on Dr. MacFarlane's management experience in the pharmaceutical industry, particularly in the area of clinical and regulatory affairs, our Board believes that Dr. MacFarlane has the appropriate set of skills to serve as a member of the Board.
2017-06-26	M. David MacFarlane, Ph.D. served as Vice President and Responsible Head of Regulatory Affairs of Genentech, Inc. from 1989 until his retirement in August 1999. Based on Dr. MacFarlane’s management experience in the pharmaceutical industry, particularly in the area of clinical and regulatory affairs, our Board believes that Dr. MacFarlane has the appropriate set of skills to serve as a member of the Board. The audit committee currently consists of Joseph A. Akers (chair), M. David MacFarlane and James R. McNab, Jr. The compensation committee currently consists of Scott A. Smith (chair), Joseph A. Akers and M. David MacFarlane. The governance committee currently consists of James R. McNab, Jr. (chair), M. David MacFarlane and Rajinder Kumar. M. David MacFarlane 2016 Total Compensation $52,083.
2018-07-02	M. David MacFarlane, Ph.D. served as Vice President and Responsible Head of Regulatory Affairs of Genentech, Inc. from 1989 until his retirement in August 1999. The audit committee currently consists of Joseph A. Akers (chair), M. David MacFarlane and James McNab. The compensation committee currently consists of Scott Smith (chair), Joseph A. Akers and M. David MacFarlane. The governance committee consists of James R. McNab, Jr., Rajinder Kumar and M. David MacFarlane. The following table summarizes compensation that our non-employee directors earned during 2017 for services as members of our Board. M. David MacFarlane, Ph.D. earned $98,460 in total compensation.
2019-11-20	M. David MacFarlane, Ph.D. (79) served as Vice President and Responsible Head of Regulatory Affairs of Genentech, Inc. from 1989 until his retirement in August 1999. ... The audit committee was formed in compliance with Section 3(a)(58)(A) of the Securities Exchange Act of 1934 (the “Exchange Act”) and currently consists of Joseph A. Akers (chair), M. David MacFarlane and James R. McNab, Jr., each of whom meets the independence requirements and standards currently established by Nasdaq and the SEC. ... The compensation committee currently consists of Scott A. Smith (chair), Joseph A. Akers and M. David MacFarlane, each of whom meets the independence requirements and standards currently established by Nasdaq. ... The nominating committee consists of James R. McNab, Jr., Rajinder Kumar and M. David MacFarlane who meet the independence requirements and standards currently established by Nasdaq.
2020-01-31	M. David MacFarlane, Ph.D.(7) Includes (i) 8,944 shares issuable upon exercise of outstanding options and (ii) 13,334 shares issuable upon exercise of outstanding warrants.
2020-05-22	Name and Address of Beneficial Owner(1) M. David MacFarlane, Ph.D.(6)
2020-11-02	M. David MacFarlane, Ph.D.(6) Includes (i) 8,944 shares issuable upon exercise of outstanding options and (ii) 13,334 shares issuable upon exercise of outstanding warrants.
2020-11-25	M. David MacFarlane, Ph.D. (80) served as Vice President and Responsible Head of Regulatory Affairs of Genentech, Inc. from 1989 until his retirement in August 1999. The audit committee currently consists of Joseph A. Akers (chair), M. David MacFarlane, Ph.D. and James R. McNab, Jr., each of whom meets the independence requirements and standards currently established by Nasdaq and the SEC. The compensation committee currently consists of Joseph A. Akers, M. David MacFarlane, Ph.D. (chair) and Scott A. Smith, each of whom meets the independence requirements and standards currently established by Nasdaq. The nominating committee consists of Joseph A. Akers, M. David MacFarlane, Ph.D. and Scott A. Smith (chair), each of whom meets the independence requirements and standards currently established by Nasdaq. M. David MacFarlane earned $60,000.
2021-11-05	M. David MacFarlane, Ph.D. (81) served as Vice President and Responsible Head of Regulatory Affairs of Genentech, Inc. from 1989 until his retirement in August 1999. ... The audit committee was formed in compliance with Section 3(a)(58)(A) of the Securities Exchange Act of 1934 (the “Exchange Act”) and currently consists of Joseph A. Akers (chair), M. David MacFarlane, Ph.D. and James R. McNab, Jr., each of whom meets the independence requirements and standards currently established by Nasdaq and the SEC. ... The compensation committee currently consists of Joseph A. Akers, M. David MacFarlane, Ph.D. (chair) and James R. McNab, Jr., each of whom meets the independence requirements and standards currently established by Nasdaq. ... The nominating committee consists of Joseph A. Akers, M. David MacFarlane, Ph.D. and James R. McNab, Jr. (chair), each of whom meets the independence requirements and standards currently established by Nasdaq.